Vision Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vision Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.44M	Sell	6,588 -42	-0.6%	-$21.5K	0.39%	49
2026 Q2	$3.29M	Sell	6,630 -69	-1%	-$30.6K	0.38%	53
2026 Q1	$2.99M	Buy	6,699 +104	+2%	+$48.5K	0.38%	50
2025 Q4	$2.99M	Buy	6,595 +29	+0.4%	+$12.5K	0.36%	50
2025 Q3	$2.57M	Sell	6,566 -306	-4%	-$128K	0.32%	54
2025 Q2	$3.06M	Buy	6,872 +307	+5%	+$141K	0.4%	48
2025 Q1	$3.18M	Buy	6,565 +1,541	+31%	+$718K	0.46%	44
2024 Q4	$2.02M	Sell	5,024 -9	-0.2%	-$4.17K	0.3%	58
2024 Q3	$2.34M	Buy	5,033 +292	+6%	+$140K	0.33%	55
2024 Q2	$2.22M	Buy	+4,741	New	+$2.06M	0.33%	57

Other funds holding VRTX

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Vision Capital Management's VRTX Position: Q3 2026 in Review

Vision Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.63% in Q3 2026, selling an estimated $21.5K and leaving 6,588 shares worth $3.44M. The position accounts for 0.39% of the portfolio, ranked #49.

Vision Capital Management first reported a position in VRTX in Q2 2024 and has held it in 10 quarters since. 930 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Vision Capital Management held 6,588 shares of Vertex Pharmaceuticals worth $3.44M as of Q3 2026.
Vision Capital Management sold 42 Vertex Pharmaceuticals shares in Q3 2026, an estimated $21.5K.
Vertex Pharmaceuticals made up 0.39% of Vision Capital Management's portfolio in Q3 2026, its #49 holding.
Vision Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
930 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Vision Capital Management's 13F filing for Q3 2026, filed 20 Oct 2026.